Type 1 diabetic NOD mice have defects in both thymic negative selection and peripheral regulation of autoreactive T cells, and induction of mixed chimerism can effectively reverse these defects. Our recent studies suggest that MHC-mismatched mixed chimerism mediates negative selection of autoreactive thymocytes in wild-type NOD and TCR-transgenic NOD.Rag1 +/+ .BDC2.5 mice. However, it remains unknown how mismatched I-A b MHC class II can mediate deletion of autoreactive T cells positively selected by I-A g7 . In the present study, we directly tested the hypothesis that mismatched MHC class II in mixed chimeras mediates deletion of cross-reactive autoreactive thymocytes. We first identify that transgenic BDC2. 5 
BDC2.5 TCD BM cells with BM cells from MHC-mismatched T cell-deficient C57BL/6 mice into lethally irradiated MHCmatched B6.H-2
g7 recipients, we demonstrate that thymic deletion of the cross-reactive transgenic T cells is dependent on MHC-mismatched donor BM-derived APCs but not on donor BM-derived T cells. Taken together, our studies indicate that MHC-mismatched mixed chimerism can mediate thymic deletion of cross-reactive autoreactive T cells that express more than one TCR. The Journal of Immunology, 2015, 194: 000-000.
I
n autoimmune type 1 diabetes (T1D), improper thymic selection leads to the presence of autoreactive T cells in the periphery that destroy the insulin producing b cells of the pancreas (1) (2) (3) . Years of work in the NOD mouse model of T1D has indicated that appearance of the autoreactive clones in the periphery is due to the failure of negative selection in the thymus (4) (5) (6) (7) . This enriched autoreactive T cell repertoire has been linked to the I-A g7 MHC class II (MHC II) molecule (8) (9) (10) . The mutation in I-A g7 (8) results in an MHC II that is both a promiscuous peptide binder and a weak peptide binder (11) (12) (13) (14) . Taken together, this has led to the hypothesis that there is insufficient MHC-TCR signaling in the thymus to properly deliver a negatively selecting signal. More recent work has proposed that negative selection is not defective in NOD mice, but that endogenous defects within NOD T cells leads to an altered positive selection event (15) , which could lead to an enhanced positive selection of autoreactive clones compared with nonautoimmune backgrounds. Regardless of the mechanism by which autoreactive clones are produced in the thymus of NOD mice, several groups have shown that negative selection of these autoreactive T cells can be induced by introduction of protective MHC. Using backcrossing experiments, negative selection of the NY4. (4) . Additionally, the CD8 + T cell clone AI4 was negatively selected by expression of H-2 nb1 when the protective MHC II molecules were expressed on .50% of DCs (16) . Using a gene therapy approach, introduction of I-Ab d or I-Ab k (to pair with endogenous I-Aa-chains) led to the negative selection of BDC15 tetramer-reactive T cells in the thymus (7). However, these approaches are not currently a clinically relevant means by which to introduce protective MHC molecules.
Induction of mixed chimerism is a clinically relevant means by which protective MHC can be introduced into T1D patients. The Ildstad and Shizuru groups reported that induction of chimerism with donor whole BM cells or purified BM stem cells reversed autoimmunity in myeloablatively conditioned NOD mice (17) (18) (19) . Our group and those of Sykes and Ildstad reported that induction of mixed chimerism under nonmyeloablative conditioning regimens reversed autoimmunity and eliminated insulitis in NOD mice (20) (21) (22) (23) (24) (25) . Furthermore, we found that induction of mixed chimerism with MHC-mismatched but not MHC-matched donor BM was capable of reversing autoimmunity and eliminating insulitis in NOD mice (20, 26) . We linked this reversal of autoimmunity to the ability of MHC-mismatched transplantation to induce the apparent negative selection of autoreactive T cells using the NOD.BDC2.5 TCR transgenic mouse model (26) . In this system, we observed the drop in CD4 + CD8 + double-positive (DP) thymocytes that is often observed in negative selection of transgenic T cell clones, as well as the overall reduction of BDC2.5 thymocytes and splenocytes. However, previous work by others with the BDC2.5 clone indicated that this I-A g7 -restricted clone (as originally isolated) did not have cross-reactivity to I-A b+ DCs (27) . Additionally, in I-A b /I-A g7 heterozygous NOD.BDC2.5 mice, the BDC2.5 T cell did not appear to undergo negative selection, and there was an expansion of protective BDC2.5 cells with endogenous Va2 expression (28) .
Our observations, coupled with work from other groups studying negative selection, led us to ask several questions about the mechanisms involved in the tolerance of BDC2.5 T cells: How can introduction of a protective MHC via hematopoietic cell transplantation (HCT) delete an autoreactive TCR-transgenic clone previously considered non-cross-reactive to I-A b ? Is the introduction of MHC-mismatched donor APCs sufficient to initiate negative selection of BDC2.5 T cells? In the present study, we found that donor APCs in the MHC-mismatched mixed chimeras can induce thymic negative selection of host-type cross-reactive autoreactive T cell clones with more than one TCR. 
Materials and Methods

Mice
Flow cytometry and cell depletion
PE-labeled BDC2.5 mimotope tetramer (I-A g7 AHHPIWARMDA) and control tetramer (I-A g7 PVSKMRMATPLLMQA) were obtained from the National Institutes of Health Tetramer Facility (Atlanta, GA). FITClabeled CD45.2 (104), CD45.1 (A20), and Vb4 (Kt4), PE-labeled Mac1 (M1/70), Gr-1 (RB6-8C5), CD4 (Gk1.5), TCRb (H57-597), and B220 (RA3-6B2); allophycocyanin-labeled CD45.2 (104); allophycocyanin-CY7-labeled CD8a (53-6.7) and CD4 (Gk1.5); and Pacific Blue CD45.1 (A20) were purchased from BD Pharmingen (San Diego, CA). FITClabeled CD11c (N418); allophycocyanin-labeled TCRb (H57-597), B220 (RA3-6B2), CD4 (GK1.5), and streptavadin; and allophycocyanin eFluor 780 B220 (RA3-6B2), streptavadin, and CD45.1 (A20) were purchased from eBioscience (San Diego, CA). T cells were depleted with biotin-CD3 (145-2c11), biotin-CD4 (GK1.5) and biotin-CD8 (53-6.72), anti-biotin MACS beads, and separation using an autoMACS machine (Miltenyi Biotec, San Diego CA). Chimerism was confirmed at the conclusion of the experiment 60-90 d after HCT as previously described (26, (29) (30) (31) . BM was prepared by flushing four leg bones and preparing a single-cell suspension. Spleen and thymus tissue was prepared by initial collagenase D digestion, followed by single-cell suspension preparation as previously described (23) . Prior to all staining, cells were first incubated with anti-CD16/CD32 blocking Ab for 5 min on ice. Ab or tetramer staining was performed for 15 min at 4˚C as previously performed (20, 21, 26, 29, (31) (32) (33) (34) (35) (36) (37) (38) (39) . Forward light scatter (FSC)/side light scatter was gated to exclude small cellular debris and to include lymphocytes and larger (high FSC) and granular (high side light scatter) cells (Supplemental Fig. 1 ). All analysis was done on living cells using either DAPI or Live/Dead (Life Technologies, Grand Island, NY) gating to exclude dead cells.
Pancreatic insulitis analysis
Analysis of insulitis was performed as previously described (21) .
Statistical analysis
Comparison of means was evaluated using unpaired two-tailed Student t tests. For comparison of mean stimulation index in T cell proliferation assays, we used the nonparametric Mann-Whitney U test with Prism version 6 (GraphPad Software, San Diego, CA). Comparison of insulitis levels was evaluated using a x 2 test comparing total insulitis plus periinsulitis to no insulitis. TCR (Fig. 1B) . Because BDC2.5 mimotope tetramer was reported to be able to identify BDC2.5 autoreactive T cells (46) , the tetramer was used to identify transgenic autoreactive CD4 + T cells in the spleen of BDC2.5-Rag1 +/+ and BDC2.5-Rag1 2/2 mice. We found that the tetramer staining intensity of CD4 + T cells from BDC2.5-Rag1 +/+ mice is much broader than that of CD4 + T cells from BDC2.5-Rag1 2/2 mice, but the latter was higher than the former. Thus, CD4 + T cells from BDC2.5-Rag1 2/2 mice were used to set a threshold for tetramer hi CD4 + T cells (Fig. 1C) . We observed that the nontransgenic TCR Va2
Results
Transgenic
+ cells existed among (Fig. 1E) . These results indicate that MHC-mismatched mixed chimerism mediates deletion of cross-reactive autoreactive T cells that probably express more than one TCR. significantly increase and stayed at ,1.5% of total TCRb + T cells during the observation period (Fig. 2B, 2D ). Whereas both groups had host-type CD45.1 2 T cells, these were residual T cells that existed before HCT, because they were not observed among CD4 + CD8 + host-type thymocytes in the chimeras (Supplemental Fig. 2 ). These results indicate that whereas TCD BM cells from both BDC2.5-Rag1 +/+ and BDC2.5-Rag1 Fig. 3 ), as described in our previous publications (26, (29) (30) (31) (Fig. 3C, 3D) . Additionally, some of the BDC2.5 T cells in the thymus and spleen also expressed additional nontransgenic Va2 + TCRs (Fig. 3E) (Fig. 4C) . Additionally, both groups had peripheral TCRb + T cells, indicative of thymic output of the T cell clones (Fig. 4D) . Combining the findings shown in Figs. 2-4 
T cells as indicated by reduction of CD4
+ CD8 + thymocytes (Fig. 1) . However, there are two complicating factors in this primary recipient model. First, reduction in DP thymocytes, although seemingly indicative of negative section, might be confounded by clonal competition for limited positive selection niches (48) . Second, analysis of peripheral T cells to determine negative selection capacity of cross-reactive clones is complicated by the existence of T cells that existed prior to HCT. To definitively evaluate whether donor APCs induced negative selection of cross-reactive BDC2. 5 Fig. 4 ) and in our previous publications (26, (29) (30) (31) +/+ TCD BM, 60-90 d after HCT, chimerism and thymic deletion were measured. Chimeric status was confirmed by analyzing the percentage of BM and splenic macrophages as well as thymic DCs as described above (Supplemental Fig. 4 ) and in our previous publications (26, (29) (30) (31) . Unlike recipients of BDC2.5-Rag1 +/+ TCD BM, there was only a small percentage drop when B6 APCs were present in the thymus (Fig. 5C ). Despite obtaining a large number of chimeras (.12), only two recipients had C57BL/6 donor-type (CD45.2 + ) chimerism .10%. Regardless of whether CD45.2 + chimerism status was ,10% or .10% in the thymus, there was little difference in the percentage of DP thymocytes (Fig. 5D) .
Finally, we evaluated the effect of thymic negative selection of cross-reactive BDC2.5 T cells on peripheral T cells. We found that the thymic deletion of BDC2. The present observations provide potential novel insights into how MHC-mismatched mixed chimerism mediates thymic deletion of host-type autoreactive T cells. We recently observed that MHCmismatched but not MHC-matched mixed chimerism was capable of reversing autoimmunity in wild-type and TCR-transgenic NOD.BDC2.5 mice (26) . It remained unclear how MHC-mismatched I-A b+ donor APCs can delete autoreactive thymocytes that typically recognize I-A g7 and have previously been identified as being I-A g7 restricted (27) . In the present study, we observed that the + TCR). It is of interest that in graft-versus-host disease studies, it has been revealed that many alloreactive T cells actually contain dual or multiple TCRs (49, 50) , a state that appears to resemble transgenic T cells from a Rag1 +/+ background. T cells with dual or multiple TCRs have also been observed in patients with autoimmune diseases (50) (51) (52) . Expression of dual TCRs has been proposed as a means by which autoreactive T cells can escape negative selection in the thymus (53, 54) , and NOD mice have been found to have an increased capacity to rearrange endogenous a-chains in transgenic T cell models, leading to altered positive selection (15) . Although we have shown that these transgenic T cells with dual or multiple TCRs are capable of being depleted via induction of MHC-mismatched mixed chimerism in transgenic NOD.BDC2.5 mice, understanding the overall contribution of autoreactive T cells with dual or multiple TCRs in wild-type animal models and humans will need to be elucidated in the future studies.
The current observations provide new answers to several old questions. First, in the mixed chimeric NOD.BDC2.5 mice with MHC-mismatched donor BM only showed a reduction of host-type autoreactive thymocytes (26) . If it is negative selection, why are the autoreactive T cells not completely deleted? Our present study shows that MHC-mismatched mixed chimerism only depleted transgenic T cells with endogenous TCRa rearrangement and expressed dual or multiple TCRs. It is unlikely that all the transgenic T cells expressed endogenous TCRa. Thus, it is unlikely that MHC-mismatched mixed chimerism will deplete all the autoreactive transgenic T cells. Additionally, owing to limited availability of anti-Va mAb, we only used anti-Va2 as an example in the present study; it is possible that other Va-chains have differential ability to be negatively selected. We also cannot rule out the possibility that the residual autoreactive BDC2.5 T cells in the mixed chimeras may have cross-reactivity to other MHC types other than H-2 b . Whether different allo-MHC types mediate depletion of autoreactive T cells that recognize different self-MHC also needs to be addressed in future studies.
Second, the original BDC2.5 clone did not exhibit any cross-re activity to I-A b (27) . It has also been reported that in BDC2.5 b/g7 mice, no negative selection of the BDC2.5 clone was observed, and in BDC2.5 b/b mice, no positive selection of BDC2.5 cells was observed (28) . Thus, how could I-A b+ DCs mediate negative selection of the BDC2.5 T cells that recognize I-A g7 in BDC2.5 mice with I-A b mixed chimerism? The ability of BMderived BDC2.5 T cells to rearrange endogenous TCRa contributes to the deletion. Our present study showed that unlike the situation in which BDC2.5 is bred into a I-A b /I-A b background, transplantation of BDC2. recipients. This suggests that deletion of BDC2.5 autoreactive T cells requires thymic DC expression of an MHCII that is not also involved in positive selection of the T cells; in other words, the positive and negative selection of the BDC2.5 T cells can be mediated by different TCRs, and the negative selection of BDC2.5 T cells in the MHC-mismatched H-2 b mixed chimeras is mediated by TCRs with endogenous TCRa-chains.
Third, because we were working with a TCR transgenic system, any apparent negative selection event could have been due to a failure of the transgenic T cells to outcompete WT T cells for positive selection niches. In the present study, we have demonstrated that deletion of autoreactive BDC2.5 T cells in the MHC-mismatched H-2 b mixed chimeras occurred in the absence of donor BM-derived TCRab + cells. We observed that when cross-reactive BDC2.5-Rag1 +/+ T cells were first selected on I-A g7 , and then encounter I-A b in the medulla, I-A b+ APCs alone were sufficient to delete the thymocytes that express endogenous TCRa, as indicated by deletion of nontransgenic Va2 + TCR. This negative selection phenotype also manifested itself in the periphery as a loss of those T cells expressing nontransgenic Va2 in the mice in which I-A b+ DCs were present.
Taken together, these data indicate that MHC-mismatched donor APCs can delete autoreactive T cells that express more than one TCR. Note that our current experimental system cannot determine whether minor Ags (in MHC-matched transplants) affect the negative selection of cross-reactive BDC2.5 T cells. However, owing to the inability of B6.H2 g7 mTECs to negatively select BDC2.5 T cells, it is unlikely that mismatched minor Ags play an important role in mediating negative selection. Additionally, how MHC-mismatched H-2 b mixed chimerism tolerizes the autoreactive T cells that do not express dual or multiple TCRs needs to be determined in future studies.
In summary, induction of mixed chimerism with MHCmismatched donor BM is a novel regimen that can cure autoimmune diseases such as T1D on multiple fronts, including re-establishing thymic negative selection (26) , elimination of peripheral autoreactive T cells and insulitis (20) (21) (22) (23) (24) (25) (26) , and tolerizing autoreactive B cells (29) . The present study is focused on dissecting the mechanism of restoring thymic negative selection. Based on our observations with transgenic NOD.BDC2.5 mice, we propose a novel mechanism whereby MHC-mismatched mixed chimerism mediates deletion of autoreactive T cells. As depicted in Fig. 7 , in nonchimeric autoimmune thymus, T cells with dual TCRs are positively selected by one TCR in the cortex. The dual TCR situation decreases the frequency of autoreactive TCRs on a single cell surface and allows for autoreactive T cells to escape negative selection in the medulla, as previously proposed (53, 55) . In the thymus of MHCmismatched (i.e., H-2 b ) mixed chimeras, both TCRs on the autoreactive thymocytes that express dual TCRs can interact with the mismatched MHC II on donor APCs in the medulla. The strong affinity of TCR-allo-MHC interaction leads to deletion of the immature autoreactive thymocytes. Future studies are needed to find out the requirement of donor-recipient MHC combinations that can mediate thymic deletion of host-type autoreactive T cells; future studies are also needed to test this hypothesis in wild-type (i.e., non-TCR-transgenic) animal models and human patients.
